Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...

Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising Phase 2 results, Cybin’s PARADIGM program has begun with significant funding ...

Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

A 29-year-old woman is helping women be more detached when it comes to dating after sharing with the world she has ...

Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

The weight loss injection tirzepatide helped Melanie Ressa lose weight and overcome food noise, emotional eating, and mental ...

Expert at UAB sheds light on the mental health phenomenon that casts a shadow over the colder months. As the days grow ...

The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement ...

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...